Therapeutic advances in hemophilia: from molecular innovation to patient-centered global care
Dushimova Z. Pashimov M. Kaibullayeva J. Danyarova L. Kultanova E. Abdilova G. Mustapayeva N.
2025Frontiers Media SA
Frontiers in Medicine
2025#12
Hemophilia A and B are uncommon inherited bleeding disorders linked to the X chromosome, resulting from a lack of coagulation factors VIII or IX, respectively. Acknowledged for centuries, hemophilia was historically a dangerous condition lacking effective treatment methods. Significant progress in the 20th century brought about clotting factor alternatives and strategies for preventive treatment. This review offers a refreshed overview of both conventional and new therapies, such as gene therapy, by assessing their advantages, drawbacks, and potential future developments. The narrative review consolidates existing information regarding the pathophysiology of hemophilia, its classification, genotype–phenotype correlations, and advancements in treatment. It examines factor replacement therapies along with newer strategies like non-factor therapies, immune tolerance induction, and gene therapy, while evaluating how these treatments affect patient quality of life and worldwide access to healthcare. While factor replacement therapy is still essential, it entails regular infusions, substantial expenses, and potential risks of inhibitor formation. Innovations such as extended half-life treatments and subcutaneous therapies have enhanced adherence and lowered bleeding rates. Gene therapy has demonstrated the possibility of prolonged natural factor production but continues to encounter issues concerning long-term safety, durability, and accessibility. Newly emerging concerns include the underrepresentation of Hemophilia B in translational research, the immunological challenges associated with vector-based platforms, and significant global disparities in accessing advanced therapies, particularly in low-resource settings. In spite of progress, inequalities in treatment remain, with around 70% of patients globally unable to access crucial therapies. Copyright
factor , gene therapy , hemophilia , immune tolerance induction , non-replacement therapy
Text of the article Перейти на текст статьи
Higher School of Medicine, Al-Farabi Kazakh National University, Almaty, Kazakhstan
JSC “Research Institute of Cardiology and Internal Diseases”, Almaty, Kazakhstan
JSC “Scientific Center of Pediatrics and Pediatric Surgery”, Almaty, Kazakhstan
Department of Nephrology, Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan
Higher School of Medicine
JSC “Research Institute of Cardiology and Internal Diseases”
JSC “Scientific Center of Pediatrics and Pediatric Surgery”
Department of Nephrology
10 лет помогаем публиковать статьи Международный издатель
Книга Публикация научной статьи Волощук 2026 Book Publication of a scientific article 2026